A polyester film including a cyclic carbodiimide compound represented by the following Formula (O-1) has good film thickness uniformity without increase in viscosity. R.sup.1 and R.sup.5 represent an alkyl group, an aryl group, or an alkoxy group; R.sup.2 to R.sup.4 and R.sup.6 to R.sup.8 represent a hydrogen atom, an alkyl group, an aryl group, or an alkoxy group; X.sup.1 and X.sup.2 represent a single bond, O, CO, S, SO.sub.2, NH, or CH.sub.2; and L.sup.1 represents a divalent linking group. ##STR00001##

A resin composition which comprises polylactic acid, does not release an isocyanate group at the time of production and has excellent hydrolysis resistance and a low environmental burden. The resin composition comprises: (A) 100 parts by weight of a resin component (component A) containing polylactic acid (component A-); (B) 0.001 to 10 parts by weight of a compound (component B) having one carbodiimide group and a cyclic structure in which first nitrogen and second nitrogen are bonded to each other via a bonding group, the cyclic structure consisting of 8 to 50 atoms; and (C) 0.001 to 2 parts by weight of at least one antioxidant (component C) selected from the group consisting of a hindered phenol-based compound, a phosphite-based compound, a phosphonite-based compound and a thioether-based compound.

A resin composition which comprises polylactic acid, does not release an isocyanate group at the time of production and has excellent hydrolysis resistance and a low environmental burden. The resin composition comprises: (A) 100 parts by weight of a resin component (component A) containing polylactic acid (component A-); (B) 0.001 to 10 parts by weight of a compound (component B) having one carbodiimide group and a cyclic structure in which first nitrogen and second nitrogen are bonded to each other via a bonding group, the cyclic structure consisting of 8 to 50 atoms; and (C) 0.001 to 2 parts by weight of at least one antioxidant (component C) selected from the group consisting of a hindered phenol-based compound, a phosphite-based compound, a phosphonite-based compound and a thioether-based compound.

The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active ingredient in plasma or in the blood stream of a warm-blooded animal. The invention also provides compositions and, and methods for making the prodrugs, and methods for using the prodrugs to treat fungal infections.

The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active ingredient in plasma or in the blood stream of a warm-blooded animal. The invention also provides compositions and, and methods for making the prodrugs, and methods for using the prodrugs to treat fungal infections.

The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

The present invention is directed to the preparation of key intermediates and synthesis of compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof.

The present invention is directed to the preparation of key intermediates and synthesis of compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof.

The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as conjugated lipomers or lipomers) containing one or more groups of the formula (iii): ##STR00001##
wherein R.sup.3 and R.sup.4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.

The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as conjugated lipomers or lipomers) containing one or more groups of the formula (iii): ##STR00001##
wherein R.sup.3 and R.sup.4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.